Background: Total hip arthroplasty (THA) is a common procedure that requires consideration of preexisting comorbidities. Factor V Leiden (FVL), an inherited thrombophilia, is one such condition that predisposes patients to venous thromboembolism (VTE, deep vein thrombosis, and pulmonary embolism). The present study aimed to characterize the risks associated with FVL patients undergoing THA and evaluate the effect of VTE chemoprophylactic agents on these risks.
Methods: A total of 544,022 adult patients who underwent primary THA for osteoarthritis indications between 2010 and October 2021 were identified in an administrative claims database. Of these, FVL was identified in 1,138 (0.21%). Patients who had and did not have FVL were matched at a 1:4 ratio (1,131 with FVL and 4,519 without FVL) based on age, sex, and Elixhauser comorbidity index. Univariable and multivariable analyses were assessed for 90-day complications. Implant survival at 5 years was assessed and compared with log-rank tests. The relative use of different chemoprophylactic agents, including aspirin, warfarin, heparin, or direct oral anticoagulant (DOAC), was assessed. Bleeding events and VTE were compared for those prescribed either aspirin or warfarin, heparin, or DOAC. A Bonferroni correction was applied.
Results: On multivariable analysis, FVL patients were found to have increased odds of 90-day deep vein thrombosis (odds ratio (OR) = 9.20), pulmonary embolism (OR = 6.89), and aggregated severe and all adverse events (OR = 4.74 and 1.98, respectively), but not elevated risk of other perioperative adverse events or 5-year reoperations. More potent chemoprophylactic agents (warfarin, heparin, DOAC) reduced, but did not completely eliminate, the increased VTE risks (without increasing bleeding events).
Conclusions: This study quantified the significantly elevated VTE risk associated with FVL patients undergoing THA. The lack of difference in other specific adverse events and 5-year reoperations is reassuring. Clearly, chemoprophylactic agents are important in this population and may need further attention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arth.2024.05.083 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of post-injury anticoagulation in the traumatic brain injury patient: A scoping review.
Injury
January 2025
Washington University School of Medicine, Department of Surgery, Section of Acute and Critical Care Surgery, USA. Electronic address:
Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality among trauma patients. The care of these patients continues to be a complex endeavor with prevention of associated complications, often requiring as much attention as that of the treatment of the primary injury. Paramount among these are venous thromboembolic events (VTE) due to their high incidence, additive effect on the risk of morbidity and mortality, and the careful balance that must be utilized in their diagnosis and treatment to prevent progression of the brain injury itself.
View Article and Find Full Text PDFSafety and Efficacy of Aspirin Compared to Enoxaparin Following Total Hip and Total Knee Arthroplasty Among Patients Who Have a History of Venous Thromboembolic Disease.
J Arthroplasty
November 2024
Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California.
Article Synopsis
- This study investigates the safety and effectiveness of aspirin compared to enoxaparin for preventing blood clots in high-risk patients undergoing total joint surgeries, specifically total knee and hip arthroplasties.
- Analyzing data from surgeries performed between 2015 and 2021, the researchers compared patients with a history of venous thromboembolism (VTE) who were given either aspirin or enoxaparin after their surgeries.
- The findings suggest that patients on aspirin had similar rates of serious complications like pulmonary embolism and deep vein thrombosis as those on enoxaparin but experienced fewer bleeding-related issues and complications overall.
Alarmingly High Rates of Deep Vein Thrombosis and Pulmonary Embolism Following Closed Reduction for Dislocated Total Hip Arthroplasty.
J Arthroplasty
November 2024
Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California.
Background: Venous thromboembolism (VTE) and dislocation are well-described complications following total hip arthroplasty (THA). However, the relationship between THA dislocation and venous thromboembolism remains unclear. This study sought to determine the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who experience a hip dislocation and subsequent closed reduction following primary THA.
View Article and Find Full Text PDFLi-Fraumeni Syndrome: Narrative Review Through a Case Report with Ten Years of Primary Tumor Remission Associated with H387 07 Supplementation.
Int J Mol Sci
October 2024
Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.
Article Synopsis
- Hereditary mutations, like those in the tumor protein 53 gene, can lead to Li-Fraumeni syndrome (LFS), increasing the risk of multiple cancers due to a precancerous environment, with limited treatment options currently available.
- Recently, metformin has been explored as a possible preventative medication targeting precancerous niches, but is still in clinical trials and lacks established treatments.
- A case study on a patient with LFS who took H387 07 extract for 11 years showed no new malignancies, suggesting polyphenol-rich extracts might be effective for cancer prevention and treatment in LFS patients.
A 50-year-old question: Can imidocarb chemoprophylaxis ensure seroconversion for babesiosis in cattle under field conditions?
Vet Parasitol
December 2024
Retired researcher at Instituto de Pesquisas Veterinárias Desidério Finamor (IPVDF), Eldorado do Sul, RS 92990-000, Brazil.
Article Synopsis
- Bovine babesiosis, caused by Babesia bovis and Babesia bigemina, significantly impacts livestock and is often treated with imidocarb in areas lacking vaccines.
- The study involved 15 heifers, with 12 receiving imidocarb and all exposed to ticks to evaluate the development of humoral immunity through seroconversion.
- Results showed that after multiple treatments, a majority of the treated heifers did develop antibodies against the parasites, but not all animals seroconverted, highlighting potential limitations in the effectiveness of the chemoprophylaxis approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!